Regenxbio (NASDAQ: RGNX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-08 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.320 | -1.580 | -0.2600 | ||||
REV | 29.210M | 22.218M | -6.992M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Regenxbio (NASDAQ: RGNX) through any online brokerage.
Other companies in Regenxbio’s space includes: Valneva (NASDAQ:VALN), Chinook Therapeutics (NASDAQ:KDNY), Syndax Pharmaceuticals (NASDAQ:SNDX), Prothena Corp (NASDAQ:PRTA) and FibroGen (NASDAQ:FGEN).
The latest price target for Regenxbio (NASDAQ: RGNX) was reported by Berenberg on Thursday, June 23, 2022. The analyst firm set a price target for 61.00 expecting RGNX to rise to within 12 months (a possible 121.50% upside). 13 analyst firms have reported ratings in the last year.
The stock price for Regenxbio (NASDAQ: RGNX) is $27.54 last updated July 6, 2022, 8:00 PM UTC.
There are no upcoming dividends for Regenxbio.
Regenxbio’s Q2 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for Regenxbio.
Regenxbio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.